PhRMA Outlines Value-Based Policies To Improve Drug Reimbursement

The notion of value-based contracts remains vague, but the drug industry is pushing a raft of policies to make it easier to base drug prices on outcomes. Industry suggestions include overhauling policies on Medicaid best price, drug discounts for public programs, rebates for private middlemen, anti-kickback laws, FDA restrictions on what drug companies may say about products during development and insurance benefit designs. Drug industry representatives are publicly talking more about basing drug prices on value, which coincides with a...